BACKGROUND: In atherosclerosis, local generation of reactive oxygen species amplifies the inflammatory response and contributes to plaque vulnerability. We used molecular imaging to test whether inhibition of NADPH oxidase with apocynin would reduce endothelial inflammatory activation and endothelial-platelet interactions, thereby interrupting progression to high-risk plaque phenotype. METHODS AND RESULTS: Mice deficient for both the low-density lipoprotein receptor and Apobec-1 were studied at 30 weeks of age and again after 10 weeks with or without apocynin treatment (10 or 50 mg/kg per day orally). In vivo molecular imaging of vascular cell adhesion molecule-1 (VCAM 1) P-selectin, and platelet glycoprotein-1bα (GPIbα) in the thoracic aorta was performed with targeted contrast-enhanced ultrasound molecular imaging. Arterial elastic modulus and pulse wave transit time were assessed using ultrahigh frequency ultrasound and invasive hemodynamic measurements. Plaque size and composition were assessed by histology. Molecular imaging in nontreated mice detected a 2-fold increase in P-selectin expression, VCAM-1 expression, and platelet adhesion between 30 and 40 weeks of age. Apocynin reduced all of these endothelial events in a dose-dependent fashion (25% and 50% reduction in signal at 40 weeks for low- and high-dose apocynin). Apocynin also decreased aortic elastic modulus and increased the pulse transit time. On histology, apocynin reduced total monocyte accumulation in a dose-dependent manner as well as platelet adhesion, although total plaque area was reduced in only the high-dose apocynin treatment group. CONCLUSIONS: Inhibition of NADPH oxidase in advanced atherosclerosis reduces endothelial activation and platelet adhesion, which are likely responsible for the arrest of plaque growth and improvement of vascular mechanical properties.
BACKGROUND: In atherosclerosis, local generation of reactive oxygen species amplifies the inflammatory response and contributes to plaque vulnerability. We used molecular imaging to test whether inhibition of NADPH oxidase with apocynin would reduce endothelial inflammatory activation and endothelial-platelet interactions, thereby interrupting progression to high-risk plaque phenotype. METHODS AND RESULTS:Mice deficient for both the low-density lipoprotein receptor and Apobec-1 were studied at 30 weeks of age and again after 10 weeks with or without apocynin treatment (10 or 50 mg/kg per day orally). In vivo molecular imaging of vascular cell adhesion molecule-1 (VCAM 1) P-selectin, and platelet glycoprotein-1bα (GPIbα) in the thoracic aorta was performed with targeted contrast-enhanced ultrasound molecular imaging. Arterial elastic modulus and pulse wave transit time were assessed using ultrahigh frequency ultrasound and invasive hemodynamic measurements. Plaque size and composition were assessed by histology. Molecular imaging in nontreated mice detected a 2-fold increase in P-selectin expression, VCAM-1 expression, and platelet adhesion between 30 and 40 weeks of age. Apocynin reduced all of these endothelial events in a dose-dependent fashion (25% and 50% reduction in signal at 40 weeks for low- and high-dose apocynin). Apocynin also decreased aortic elastic modulus and increased the pulse transit time. On histology, apocynin reduced total monocyte accumulation in a dose-dependent manner as well as platelet adhesion, although total plaque area was reduced in only the high-dose apocynin treatment group. CONCLUSIONS: Inhibition of NADPH oxidase in advanced atherosclerosis reduces endothelial activation and platelet adhesion, which are likely responsible for the arrest of plaque growth and improvement of vascular mechanical properties.
Authors: Zaverio M Ruggeri; Jennifer N Orje; Rolf Habermann; Augusto B Federici; Armin J Reininger Journal: Blood Date: 2006-06-13 Impact factor: 22.113
Authors: Owen J T McCarty; Robert B Conley; Weihui Shentu; Garth W Tormoen; Daogang Zha; Aris Xie; Yue Qi; Yan Zhao; Chad Carr; Todd Belcik; Douglas R Keene; Philip G de Groot; Jonathan R Lindner Journal: JACC Cardiovasc Imaging Date: 2010-09
Authors: Beat A Kaufmann; Chad L Carr; J Todd Belcik; Aris Xie; Qi Yue; Scott Chadderdon; Evan S Caplan; Jaspreet Khangura; Sherry Bullens; Stuart Bunting; Jonathan R Lindner Journal: Arterioscler Thromb Vasc Biol Date: 2009-10-15 Impact factor: 8.311
Authors: Beat A Kaufmann; John M Sanders; Christopher Davis; Aris Xie; Patrick Aldred; Ian J Sarembock; Jonathan R Lindner Journal: Circulation Date: 2007-06-25 Impact factor: 29.690
Authors: Tamara Atkinson; William Packwood; Aris Xie; Sherry Liang; Yue Qi; Zaverio Ruggeri; Jose Lopez; Brian P Davidson; Jonathan R Lindner Journal: J Am Soc Echocardiogr Date: 2018-09-11 Impact factor: 5.251
Authors: Chi Young Shim; Ya Ni Liu; Tamara Atkinson; Aris Xie; Ted Foster; Brian P Davidson; Mackenzie Treible; Yue Qi; José A López; Adam Munday; Zaverio Ruggeri; Jonathan R Lindner Journal: Circ Cardiovasc Imaging Date: 2015-07 Impact factor: 7.792
Authors: I M Quesada; A Lucero; C Amaya; D N Meijles; M E Cifuentes; P J Pagano; C Castro Journal: Atherosclerosis Date: 2015-08-08 Impact factor: 5.162
Authors: Federico Moccetti; Eran Brown; Aris Xie; William Packwood; Yue Qi; Zaverio Ruggeri; Weihui Shentu; Junmei Chen; Jose A López; Jonathan R Lindner Journal: J Am Coll Cardiol Date: 2018-08-28 Impact factor: 24.094
Authors: Y Ajith; U Dimri; S K Dixit; Shanker K Singh; A Gopalakrishnan; E Madhesh; J B Rajesh; S G Sangeetha Journal: Inflammopharmacology Date: 2017-09-01 Impact factor: 4.473